Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the immunogenic potential of the liquid
formulation of omalizumab administered over a period of 6 months in moderate to severe
persistent allergic asthma patients 12 years of age or older, with no previous exposure to
the drug (omalizumab naïve patients). The secondary objective of this study is to assess the
safety of the liquid formulation of omalizumab in the same patients.